Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S1. Patient Characteristics.</p>

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Qingsheng Xu (17078830) (author)
Beste egile batzuk:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Argitaratua:	2025
Gaiak:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
nork: Qingsheng Xu (17078830)
Argitaratua: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
nork: Tobias Kessler (17079209)
Argitaratua: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
nork: William Kelly (15439117)
Argitaratua: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
nork: William Kelly (15439117)
Argitaratua: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
nork: Dwight H. Owen (15034782)
Argitaratua: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
nork: Dwight H. Owen (15034782)
Argitaratua: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
nork: Dwight H. Owen (15034782)
Argitaratua: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
nork: Dwight H. Owen (15034782)
Argitaratua: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
nork: Dwight H. Owen (15034782)
Argitaratua: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
nork: Tom Wei-Wu Chen (15053003)
Argitaratua: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
nork: Tom Wei-Wu Chen (15053003)
Argitaratua: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
nork: Tom Wei-Wu Chen (15053003)
Argitaratua: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
nork: Tom Wei-Wu Chen (15053003)
Argitaratua: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
nork: Tom Wei-Wu Chen (15053003)
Argitaratua: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
nork: James S. Wilmott (15008931)
Argitaratua: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
nork: James S. Wilmott (15008931)
Argitaratua: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
nork: John A. Ligon (15024477)
Argitaratua: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
nork: Giuseppe Basile (15051269)
Argitaratua: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
nork: Andrés Elía (15055031)
Argitaratua: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
nork: Andrés Elía (15055031)
Argitaratua: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
nork: Andrés Elía (15055031)
Argitaratua: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
nork: Andrés Elía (15055031)
Argitaratua: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
nork: Andrés Elía (15055031)
Argitaratua: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
nork: Roger Li (17078665)
Argitaratua: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
nork: Ulka N. Vaishampayan (15051039)
Argitaratua: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
nork: Ulka N. Vaishampayan (15051039)
Argitaratua: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
nork: Ulka N. Vaishampayan (15051039)
Argitaratua: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
nork: Ulka N. Vaishampayan (15051039)
Argitaratua: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
nork: Nigel Bundred (15046233)
Argitaratua: (2025)

Cannot write session to /tmp/vufind_sessions/sess_76rvr6hjjq4r46suoj3btrtl41